Skip to main content
. 2015 Nov 25;5:16768. doi: 10.1038/srep16768

Figure 4.

Figure 4

TRPV1 and TRPA1 were not required for NaHS-induced itch, while TRPV1 was required for NaHS-induced pain in mice. (A) Local administration of TRPV1 antagonist capsazepine (10–50 μg) did not affect NaHS-induced scratching. (B) In cheek model, co-administration of capsaizepine (50 μg) suppressed NaHS-induced forelimb wiping, but not hindpaw scratching. (C) Intraplantar co-administration of capsazepine (50 μg) attenuated NaHS-induced flinching. (D) Local administration of TRPA1 antagonist HC-030031 (10–50 μg) did not affect NaHS-induced scratching. (E) In cheek model, co-administration of HC-030031 (50 μg) did not affect NaHS-induced both forelimb wiping and hindpaw scratching. (F) Intraplantar co-administration of HC-030031 (50 μg) had no effects on NaHS-induced flinching. All data are expressed by means ± SEM. n = 6–8 mice per group. *P < 0.05; **P < 0.01, ***P < 0.001 vs. vehicle control, Student’s t test.